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Abstract
Objectives: Pyruvate kinase (PK) deficiency is caused by PKLR gene mutations, leading to defective red blood cell glycolysis and hemolytic anemia. Rates of comorbidities and complications by transfusion history and relative to the general population
remain poorly quantified.
Methods: Data for patients aged ≥ 18 years with two confirmed PKLR mutations
were obtained from the PK deficiency Natural History Study (NCT02053480).
Frequencies of select conditions were compared with an age- and sex-matched cohort from a general insured US population without PK deficiency.

Novelty Statements: What is the new aspect of your work?: The rates of key co-occurring conditions in patients with pyruvate kinase (PK) deficiency are assessed according to blood
transfusion history and are compared with the rates in the matched general population. What is the central finding of your work?: Patients with PK deficiency have higher rates of select
comorbidities and complications than matched individuals from the general population, and these can occur even in patients who have never been transfused. What is (or could be) the
specific clinical relevance of your work?: These findings raise awareness about the excess disease burden experienced by patients with PK deficiency and should alert clinicians to monitor
these patients for certain comorbidities and complications, regardless of the perceived severity of their illness as measured by transfusion requirements.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in
any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 Agios Pharmaceuticals, Inc. European Journal of Haematology Published by John Wiley & Sons Ltd
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Results: Compared with the matched population (n = 1220), patients with PK deficiency (n = 122) had significantly higher lifetime rates of osteoporosis, liver cirrhosis, and pulmonary hypertension; splenectomy and cholecystectomy rates were also
significantly higher in the 8 years before the index date. Sixty-five (53.3%) patients
with PK deficiency were classified as regularly transfused, 30 (24.6%) as occasionally
transfused, and 27 (22.1%) as never transfused. Regularly transfused patients were
significantly more likely than never transfused patients to have had splenectomy,
cholecystectomy, and/or thrombosis. Liver iron overload was reported in 62% of patients and occurred regardless of transfusion cohort.
Conclusions: Even never transfused patients with PK deficiency had higher rates of
select comorbidities and complications than individuals without PK deficiency.
KEYWORDS

blood transfusion, comorbidity, pyruvate kinase deficiency

1 | I NTRO D U C TI O N

deficiency and (b) better understand the impact of transfusion history on the prevalence of comorbidities and complications in adults

Pyruvate kinase (PK) deficiency is a rare congenital disorder caused by

with PK deficiency.

autosomal recessive mutations in the liver- and red cell-specific PKLR
gene, leading to a defect in the glycolytic pathway in red blood cells
and hereditary hemolytic anemia.1-3 This glycolytic defect leads to a re-

2 | M E TH O DS

duction in adenosine triphosphate, and shortened reticulocyte and red
cell lifespans due to an inability to maintain the red cell electrochemical

This was a retrospective analysis of cross-sectional data from two

gradient and membrane integrity.4 As a consequence, damaged PK-

separate data sources, attempting to estimate the lifetime preva-

defective erythrocytes undergo brisk hemolysis in the spleen.2,5

lence of select conditions based on reported medical history.

The diagnosed prevalence of PK deficiency in the general population is estimated to be between 3.2 and 8.5 cases per million individuals.6-10 Higher prevalence is observed in specific populations,
such as in the US Amish community, due to the founder effect.11,12

2.1 | Data source and inclusion criteria: PK
deficiency population

In addition to anemia, PK deficiency is associated with serious
complications. Estimates of complication rates observed in 254 pe-

The PK deficiency NHS is a longitudinal, retrospective, and pro-

diatric and adult patients in the PK deficiency Natural History Study

spective cohort study that enrolled 278 patients with biochemically

(NHS) include iron overload (48%), gallstones (45%), and bone frac-

or molecularly diagnosed PK deficiency from June 2014 to April

13

Furthermore, PK deficiency has been shown to nega-

2017 at 31 centers in six countries in North America and Europe

tively affect quality of life due to impacts on physical, emotional, and

(ClinicalTrials.gov NCT02053480).13 The study protocol was ap-

ture (17%).

14

social functioning.

proved by each site's Institutional Review Board and/or ethics com-

Current management of PK deficiency is supportive and includes

mittee, and all patients gave informed consent. Patient demographics

red blood cell transfusions, iron chelation therapy, and/or splenec-

and clinical, laboratory, transfusion, and radiologic data were col-

tomy.15 Both the hemolysis and supportive treatments are associ-

lected in a case report form completed by the site, based on medical

ated with short- and long-term risks. Splenectomy is associated with

record review. When medical records were not available, data were

the risk of thrombosis and pulmonary hypertension16; transfusions

either reported as missing or a patient report was used, when possi-

are associated with iron loading. Hemolysis is associated with trans-

ble. This analysis of comorbidities and complications focused only on

fusion-associated and transfusion-independent iron loading, as well

the retrospective data collected at the time of patients' enrollment

as extramedullary hematopoiesis, osteopenia, and pigmented gall-

in the PK deficiency NHS, and not the prospective data collected

stones.1,15 There are currently no approved pharmacologic options

over the 2 years following enrollment. The inclusion criteria for this

for altering the disease pathophysiology of PK deficiency.

analysis were age ≥ 18 years at the time of enrollment, diagnosis of

The aims of this analysis were to (a) compare prevalence rates of

PK deficiency by molecular testing (two confirmed mutations in the

comorbidities and complications among adults with PK deficiency

PKLR gene), and sufficient data on transfusion history to enable clas-

with those observed in a general insured US population without PK

sification into one of three mutually exclusive cohorts.
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date. Medical conditions and procedures were identified using ICD9-CM, ICD-10-CM, Current Procedural Terminology, and Healthcare

The regularly transfused cohort included patients who received

Common Procedure Coding System codes.

six or more transfusions over any 12-month period, the occasionally transfused cohort included patients who had received transfusions in the past but never more than four in a single year, and the

2.4 | Data analysis and statistical interpretation

never transfused cohort included patients who had never received
a transfusion.

Data on comorbidities and complications extracted from the PK

Baseline demographic characteristics, clinical characteristics,

deficiency NHS represented the lifetime history of comorbidities.

transfusion history, medical conditions, procedures, and medication

Conversely, claims data did not include entire medical histories but

use were collected from the PK deficiency NHS enrollment survey.

only included diagnosis codes for conditions that were diagnosed

Unless otherwise noted, medical conditions were reported as life-

and/or treated in the years during which the patient had continuous

time history. Diagnosis and procedure dates were collected in the

enrollment in the health plan, previously diagnosed conditions that

PK deficiency NHS for select conditions and events. Select medical

were medically relevant and coded during their time in the health

procedures were also reported.

plan, or conditions for which a “history of” an ICD-9-CM or ICD10-CM code exists and the patient's physician chose to include the

2.3 | Data source and inclusion criteria: matched
general population

code in the patient's record. Thus, there was a risk of a relative underreporting of conditions in the general population that occurred
prior to the enrollment period (eg, during childhood) and were fully
resolved and/or did not warrant any medical follow-up. To minimize

The frequencies of select conditions and procedures observed in

this risk of bias, comparisons were limited to certain conditions, and

the PK deficiency NHS population were compared with age- and

two different analytic approaches were used: (a) A focus on condi-

sex-matched cohorts of individuals without any hereditary or ac-

tions that were chronic and required ongoing management and thus

quired hemolytic anemia diagnoses (ie, International Classification

would be expected to appear in claims data, regardless of how long

of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] codes

ago the condition was initially diagnosed (osteoporosis, pulmonary

282 and 283; ICD, 10th Revision, CM [ICD-10-CM] codes D55-

hypertension, and liver cirrhosis); and (b) a narrowing of the observa-

D59) who had ≥ 5 years of continuous enrollment in one of three

tion window for the PK deficiency population to be aligned with the

US MarketScan® (Truven, IBM Watson Health) Research Databases.

average 8-year observation window for the general population, with

Patients with PK deficiency are typically coded in claims data with

a focus only on conditions for which a diagnosis or procedure date

one of these codes, as there is no specific ICD-9-CM or ICD-10-CM

was available in the PK deficiency NHS population, so that events

code for PK deficiency. Excluding patients with any hereditary or

(such as splenectomy, cholecystectomy, gallstones, and congestive

acquired hemolytic anemia helped ensure no patients with PK defi-

heart failure) that occurred prior to the narrowed observation win-

ciency were included in the comparator population. The MarketScan

dow could be distinguished and excluded from the analysis. As it was

databases include anonymized inpatient, outpatient, and outpatient

not possible to identify conditions that had not yet been diagnosed,

prescription drug claims data for ~205 million individuals insured

prevalence rates reported for both the PK deficiency population and

commercially or as part of the national Medicare or Medicaid pro-

the matched general population represented diagnosed prevalence

grams between 1995 and 2017. All patients who met the study eligi-

rather than actual disease prevalence. Prevalence data on comor-

bility requirements in these databases were included in the sampling

bidities and complications were tabulated by transfusion cohort and

frame for this study. For the MarketScan analyses, all database re-

in aggregate, and compared using Fisher's exact two-tailed tests of

cords are de-identified and fully compliant with US patient confiden-

significance. Results were deemed significant when the P value was

tiality requirements, including the Health Insurance Portability and

<.05. Adjustments were not made for multiple comparisons given the

Accountability Act of 1996. Because this study used de-identified

exploratory nature of this analysis, the danger of missing clinically im-

patient records and did not involve the collection, use, or transmittal

portant findings introduced by penalizing results, and increasing the

of individually identifiable data, Institutional Review Board approval

risk of type II error in a rare disease setting where data are limited.17,18

for this analysis was not necessary.
Individuals in the MarketScan databases were matched at a 1:10
(PK deficiency NHS:MarketScan) ratio based on age (±1 year), sex,
and year of enrollment in the PK deficiency NHS.
Baseline demographic characteristics were reported as of the

3 | R E S U LT S
3.1 | Study populations

index date, which was designated as the midpoint of the year of the
corresponding matched PK deficiency NHS patient's study enroll-

Of the 254 patients with two confirmed mutations of the PKLR gene

ment year. All matched patients were required to have a minimum

in the PK deficiency NHS, 131 patients met the inclusion criteria of

of 5 years of continuous enrollment immediately prior to the index

being aged ≥ 18 years. Of these, nine could not be categorized into

12 (18.5)

1 (1.5)

Non-missense/
non-missense

Othera
2 (6.7)

2 (6.7)

8 (26.7)

0

0

5 (18.5)

19 (70.4)

3 (11.1)

1 (3.7)

27 (100)

37.2 (16.3)

16 (59.3)

Never transfused cohort
(n = 27)

.085

>.999

>.999

.083

.383

Regularly transfused vs occasionally
transfused cohorts

.003

>.999

>.999

.383

.360

Regularly transfused vs
never transfused cohorts

Three patients could not be classified due to having three variants (n = 1) or due to having a promoter variant of uncertain significance (n = 2).

a

Note: The general population (n = 1220; data not shown) was age and sex matched to the pyruvate kinase deficiency population. The percent male and mean age across each transfusion cohort were
identical to the pyruvate kinase deficiency population. Race, ethnicity, Amish status, and genotype were either not available or not applicable. For sex, race, and ethnicity, comparisons are based on a twotailed Fisher's exact test. For age, comparisons are based on a two-sample t test. For genotype, comparisons are based on a chi-square test.

21 (32.3)

11 (16.9)

Missense/missense

Missense/non-missense

Amish R479H/R479H

1 (3.3)

30 (100)

14 (46.7)

2 (3.1)

Hispanic or Latino, n (%)
4 (13.3)

63 (96.9)

White, n (%)

39.5 (14.7)

17 (56.7)

Occasionally transfused cohort
(n = 30)

20 (30.8)

34.2 (11.0)

Genotype, n (%)

30 (46.2)

Mean (SD) age, y

Regularly transfused cohort
(n = 65)

P value

Baseline demographics and characteristics of the Pyruvate Kinase deficiency Natural History Study population

Male, n (%)

TA B L E 1
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3.2.2 | Comorbidities and complications: restricted
observation window

a transfusion cohort (two patients had regular transfusions at a frequency of five transfusions over a 12-month period and seven patients had missing transfusion data that prohibited categorization).
Therefore, the final PK deficiency study sample consisted of 122

Of the conditions and procedures that were assessed based on rates

adults: 65 (53.3%) were included in the regularly transfused cohort,

over the 8 years leading up to the index date, patients with PK defi-

30 (24.6%) in the occasionally transfused cohort, and 27 (22.1%) in

ciency had significantly higher rates than the general population for

the never transfused cohort.

splenectomy (4.9% vs 0.2%, respectively; P < .001), cholecystectomy

The 122 adult patients with PK deficiency were matched to 1220

(13.1% vs 3.6%; P < .001) (Figure 2), and gallstones (16.9% vs 4.3%;

individuals from the general population; individuals from the general

P < .001). Rates of congestive heart failure over the previous 8 years

population had an average of 8.1 years of continuous enrollment.

were not significantly different between the two populations.

Baseline demographics and characteristics are shown in Table 1.
The transfusion cohorts were not different with regard to age at en-

3.3 | Comorbidities and complications in the PK
deficiency NHS population

rollment, sex, race, or ethnicity. Twenty-seven Amish patients (homozygous for the R479H splice variant) accounted for 22.1% of the
PK deficiency study population and the majority of these patients
(n = 20) were in the regularly transfused cohort (30.8% of the regu-

For conditions for which unbiased lifetime comparisons with the

larly transfused cohort). Patients with a non-missense/non-missense

general population could not be made, lifetime prevalence rates

PKLR genotype were more likely to be in the regularly transfused

just for the PK deficiency NHS population, stratified by transfusion

cohort than in the never transfused cohort.

cohort, are presented in Table 2. Statistically significant differences
between transfusion cohorts were observed for splenectomy, cholecystectomy, aplastic crises, thrombosis, and liver iron overload.

3.2 | Comparisons with matched general population

For many conditions, a gradient could be seen, with the highest
rates reported for patients in the regularly transfused cohort and the

3.2.1 | Comorbidities and complications: lifetime rate

lowest rates in the never transfused cohort. For liver iron overload,
the highest rates were observed in the regularly transfused cohort

Osteoporosis, pulmonary hypertension, and liver cirrhosis were the

(83.1%). However, notably, 25.9% of patients in the never transfused

only conditions captured in the PK deficiency NHS that are chronic

cohort were reported to have a history of liver iron overload de-

in nature, require ongoing management, and/or would be expected

spite never receiving a transfusion. Rates of extramedullary hema-

to appear in claims data regardless of how long ago the condition

topoiesis were numerically higher in the regularly transfused cohort

was initially diagnosed. Rates of all of these conditions were signif-

vs the occasionally transfused cohort (22.4% vs 4.8%, respectively

icantly higher in patients with PK deficiency than in the matched

[P = .092], vs 9.1% in the never transfused cohort [P = .319]). A his-

general population: pulmonary hypertension (4.6% vs 0.3%, respec-

tory of thrombosis correlated with splenectomy status and was ob-

tively; P < .001), osteoporosis (15.6% vs 0%; P < .001), and liver cir-

served in 16 (13.3%) patients in the PK deficiency population, with

rhosis (5.6% vs 0.4%; P < .001) (Figure 1).

the majority being in the regularly transfused cohort (13 [20.0%]

25

Regularly transfused cohort

**
21.2

Occasionally transfused cohort
Never transfused cohort

Rate (%)

20

**
15.6

15

10

*

8.7

All patients with PK deficiency
Matched population

*

11.1

*

9.5

**
5.6

*

5.3

5
0

0
Osteoporosis

*

5.5
3.8 3.7

0

0.4

Liver cirrhosis

**
4.6
0.3

Pulmonary
hypertension

F I G U R E 1 Comparison of lifetime
prevalence estimates of select
comorbidities and complications between
the PK deficiency NHS population and
matched patients from MarketScan data.
All comparisons are based on a twotailed Fisher's exact test. *P < .05 for PK
deficiency NHS population vs matched
general population. **P < .001 for PK
deficiency NHS population vs matched
general population. NHS, Natural History
Study; PK, pyruvate kinase

|
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15

All patients with PK deficiency

*
13.1

Matched population

489

regularly transfused cohort and one in the occasionally transfused
cohort) and one case occurred in a non-splenectomized patient in
the never transfused cohort. The prevalence of sepsis was not different between transfusion cohorts or by splenectomy status.
The association between transfusion cohort and liver iron over-

10
Rate (%)

load was no longer significant when splenectomy was added to a
logistic regression model. However, this finding may not be related

5

to the splenectomy, but rather to greater underlying disease severity

*
4.9

in patients who were splenectomized.
Given the relatively high proportion of Amish patients in the PK

3.6
2.5
0.2

0
Cholecystectomy

Splenectomy

0

Congestive
heart failure

F I G U R E 2 Comparison of prevalence estimates of select
comorbidities and complications limited to an average of 8 y prior
to enrollment in PK deficiency NHS or index date in MarketScan.
*P < .001 for PK deficiency NHS population vs matched general
population. NHS, Natural History Study; PK, pyruvate kinase

deficiency study adult population (22.1%) and concerns of possible
confounding due to potential differences in clinical characteristics
or treatment patterns in this population, a subgroup analysis restricted to the non-Amish patients was conducted. Although limited
by small sample sizes in the transfusion cohorts, the results were
consistent with findings for the full population (Amish and nonAmish patients), with the exception that gallstones over the previous
8 years were less common in the regularly transfused cohort of the
non-Amish population (7.0%) than the regularly transfused cohort
of the full population (16.9%). This is likely attributable to screening ultrasounds performed as part of the PK deficiency NHS for the
Amish cohort as compared with the non-Amish cohort, and/or with
the lower lifetime rates of cholecystectomy among Amish patients

patients) compared with 3 (10.0%) in the occasionally transfused

(41.4% vs 65.6% for non-Amish patients; P = .029) that left them at

cohort (P = .376) and no patients in the never transfused cohort

ongoing risk of gallstones in the 8 years prior to enrollment.

(P = .016).
Because all 65 patients in the regularly transfused cohort had
been splenectomized, compared with only 20 of 30 (66.7%) patients

4 | D I S CU S S I O N

in the occasionally transfused cohort and 6 of 27 (22.2%) patients
in the never transfused cohort (P < .001 for regularly transfused

The aim of this analysis was to compare the prevalence of select co-

vs occasionally transfused and regularly transfused vs never trans-

morbidities and complications in patients with PK deficiency with

fused; P = .001 for occasionally transfused vs never transfused), ad-

age- and sex-matched individuals without PK deficiency, and to

ditional analyses were performed whereby patients were stratified

determine if the prevalence of conditions in patients with PK defi-

by splenectomy status rather than transfusion history. Thrombosis

ciency varies by transfusion history. Patients with PK deficiency had

occurred in 16 of 90 (17.8%) splenectomized patients vs 0 of 30

higher lifetime rates of pulmonary hypertension, osteoporosis, and

non-splenectomized patients (P = .011). The majority of patients (14

liver cirrhosis, and higher 8-year rates of splenectomy, gallstones,

of 16) experienced thrombotic events postsplenectomy (11 from the

and cholecystectomy than age- and sex-matched individuals from a

regularly transfused cohort and 3 from the occasionally transfused

general insured US population who did not have PK deficiency.

cohort).

The purpose of comparing with an age- and sex-matched popula-

Gallstones and iron overload were more commonly observed in

tion of patients without PK deficiency was to contextualize the rates

patients who underwent splenectomy, likely related to the greater

of comorbidities and complications previously reported in the PK

severity of hemolysis in patients who underwent splenectomy.

deficiency literature, and to demonstrate that regardless of trans-

Although gallstones were frequently reported among non-sple-

fusion status, patients with PK deficiency have measurable disease

nectomized patients (15 of 30 [50.0%] patients), they were sig-

burden that exceeds what would be seen in the general population.

nificantly more common among patients who had a splenectomy

Comparisons with the general population are particularly helpful for

(65 of 88 [73.9%]; P = .023). Similarly, iron overload was also sig-

healthcare decision makers who may not be familiar with the disease

nificantly more common among splenectomized patients (72 of

and prefer a familiar benchmark to help prioritize policies, interven-

91 [79.1%]) than non-splenectomized patients (four of 31 [12.9%];

tions, and other treatment-related decisions.

P < .001).

Evaluation of the individual transfusion cohorts in the PK defi-

The rates of pulmonary hypertension in the splenectomized

ciency population revealed significant differences in occurrence of

subgroup were not statistically significantly different from non-sple-

splenectomy, cholecystectomy, aplastic crises, thrombosis, and liver

nectomized patients. However, of the five cases of pulmonary hy-

iron overload between those in the never transfused, occasionally

pertension, four occurred in splenectomized patients (three in the

transfused, or regularly transfused cohorts, with the latter cohort

490
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TA B L E 2 General, hematologic, and endocrine comorbid conditions and complications in the Pyruvate Kinase deficiency Natural History
Study population
P value
Regularly
transfused
cohort,
n/N (%)
(n = 65)

Occasionally
transfused
cohort,
n/N (%)
(n = 30)

Never
transfused
cohort,
n/N (%)
(n = 27)

All patients
with PK
deficiency,
n/N (%)
(n = 122)

Arrhythmia

5/62 (8.1)

5/28 (17.9)

1 (3.7)

11/117 (9.4)

Congestive heart failure

2/62 (3.2)

1/28 (3.6)

0 (0)

Pulmonary hypertension

3/55 (5.5)

1/26 (3.8)

1 (3.7)

Osteoporosis

11/52 (21.2)

2/23 (8.7)

2/21 (9.5)

Liver cirrhosis

3/57 (5.3)

3/27 (11.1)

0/24 (0)

Bone enlargement/bony
expansion

8/60 (13.3)

1/24 (4.2)

Extramedullary hematopoiesis

11/49 (22.4)

Liver iron overload
Cardiac iron overload
History of thrombosis

Regularly
transfused vs
occasionally
transfused
cohorts

Occasionally
transfused
vs never
transfused
cohorts

Regularly
transfused
vs never
transfused
cohorts

Chronic diseases
.275

.193

.663

3/117 (2.6)

>.999

>.999

>.999

5/108 (4.6)

>.999

>.999

>.999

15/96 (15.6)

.321

>.999

.323

6/108 (5.6)

.381

.238

.551

0/25 (0)

9/109 (8.3)

.435

.490

.098

1/21 (4.8)

2/22 (9.1)

14/92 (15.2)

.092

>.999

.319

54 (83.1)

15 (50.0)

7 (25.9)

76 (62.3)

.001

.102

<.001

2/34 (5.9)

0/4 (0.0)

0/3 (0.0)

2/41 (4.9)

NC

>.999

Hematological conditions

>.999

13 (20.0)

3 (10.0)

0/25 (0)

16/120 (13.3)

.376

.242

.016

Deep vein thrombosis

7 (10.8)

2 (6.7)

0/25 (0)

9/120 (7.5)

.715

.495

.184

Pulmonary embolism

5 (7.7)

1 (3.3)

0/25 (0)

6/120 (5.0)

.661

.317

>.999

Stroke

1 (1.5)

1 (3.3)

0/25 (0)

2/120 (1.7)

.534

>.999

>.999

Other

3 (4.6)

1 (3.3)

0/25 (0)

4/120 (3.3)

>.999

>.999

.557

Central venous line

2 (3.1)

1 (3.3)

0/25 (0)

3/120 (2.5)

>.999

>.999

>.999

Presplenectomy thrombosis

1 (1.5)

0 (0)

0/25 (0)

1/120 (0.8)

>.999

>.999

>.999

Postsplenectomy thrombosis

11 (16.9)

3 (10.0)

0/25 (0)

14/120 (11.7)

.537

.242

.031

11/65 (16.9)

3/20 (15.0)

0/6 (0)

14/91 (15.4)

>.999

>.999

.580

Growth hormone deficiency

2/59 (3.4)

1/27 (3.7)

0/23 (0)

3/109 (2.8)

>.999

>.999

>.999

Hypoparathyroidism

3/59 (5.1)

0/21 (0)

0/23 (0)

3/103 (2.9)

.563

Thyroid disease

Postsplenectomy thrombosis

a

Endocrine conditions
NC

.556

6/63 (9.5)

2/27 (7.4)

2/24 (8.3)

10/114 (8.8)

>.999

>.999

>.999

Hypothyroidism

5/63 (7.9)

1/27 (3.7)

1/24 (4.2)

7/114 (6.1)

NC

NC

NC

Hyperthyroidism

0/63 (0)

0/27 (0)

1/24 (4.2)

1/114 (0.9)

NC

NC

NC

Unknown

1/63 (1.6)

1/27 (3.7)

0/24 (0)

2/114 (1.8)

NC

NC

NC

Splenectomy

65 (100.0)

20 (66.7)

6 (22.2)

91 (74.6)

<.001

.001

<.001

Cholecystectomy

46 (70.8)

19 (63.3)

8 (29.6)

73 (59.8)

.485

.017

<.001

Gallstones

47/63 (74.6)

20/28 (71.4)

13 (48.1)

80/118 (67.8)

.799

.102

.027

Leg ulcers

3/58 (5.2)

1/27 (3.7)

0/23 (0)

4/108 (3.7)

>.999

>.999

.554

Aplastic crises

13/59 (22.0)

8/27 (29.6)

0 (0)

21/113 (18.6)

.589

.004

.007

Bone fracture

20/61 (32.8)

6/24 (25.0)

6/23 (26.1)

32/108 (29.6)

.604

>.999

.608

Sepsis

3 (4.6)

1/29 (3.4)

1/26 (3.8)

5/120 (4.2)

>.999

>.999

>.999

Other conditions/events

Note: Denominators are only specified when data for the full cohort are not available.
Note:Liver iron overload is defined as patients meeting any of the following criteria: (a) Ever received chelation therapy, (b) Ever been prescribed
phlebotomy for iron removal, (c) had ferritin > 1000 ng/mL in the 12 mo prior to enrollment, (d) biopsy liver iron concentration > 3 mg Fe/g DW,
(e) T2 magnetic resonance imaging liver iron concentration > 3 mg Fe/g DW, or (f) Ferriscan liver iron concentration > 3 mg Fe/g DW. Cardiac iron
overload is defined as T2 ≤ 20 ms.
Abbreviations: DW, dry weight; NC, not calculated; PK, pyruvate kinase.
a

Limited denominator to patients who had a splenectomy. All comparisons are based on a two-tailed Fisher's exact test.
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typically having the highest rates. However, even patients with PK
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which constitutes < 10% of the US population, were not included.

deficiency in the never transfused cohort were shown to have sig-

Additionally, the PK deficiency NHS is a multinational registry; how-

nificant complications, including liver iron overload, gallstones, oste-

ever, the general population data are restricted to individuals in the

oporosis, and extramedullary hematopoiesis.

United States and contain very limited information on ethnic back-

In order to optimize treatment of patients with PK deficiency,

ground. Accordingly, we were unable to assess any possible impact of

it is important to distinguish the complications that are due to the

ethnicity differences on study outcomes. Despite the international

disease itself compared with those that occur as a result of treat-

effort, the PK deficiency NHS cohort included a limited number

ment, such as splenectomy and transfusions. Splenectomy, in gen-

of patients. Therefore, it remains necessary to continue to expand

eral, increases the risk of venous thromboembolism, including in

upon the collection of longitudinal data on the natural history of pa-

individuals with PK deficiency. Given that the majority of throm-

tients affected by PK deficiency, with a view to better understand

botic events occurred postsplenectomy, this risk is likely to be re-

the disease burden and inform physicians on how to manage this

lated to the splenectomy rather than the anemia.19 In addition to

patient population. This longitudinal data will continue to be col-

thrombosis, patients who underwent splenectomy in this study had

lected through the PK deficiency Global Longitudinal Registry (Peak

a high rate of liver iron overload. Splenectomy may be a marker of,

Registry; ClinicalTrials.gov NCT03481738).

or correlate with, a more severe hemolytic phenotype with a greater

The rate of comorbidities and complications are significantly

degree of iron absorption, but the rate of splenectomy was also high-

higher in the PK deficiency population than a general insured US

est in those in the regularly transfused cohort, with a greater risk

population. This analysis has also demonstrated the high rate of co-

of transfusion-related iron loading. In this setting, splenectomy is

morbidities and complications in adults with PK deficiency regard-

often performed to minimize transfusional iron burden. Iron over-

less of transfusion status, and the impact of transfusion frequency

load is a serious consequence of PK deficiency, occurring regardless

on the prevalence of these comorbidities.

of transfusion or splenectomy status. 20 Even patients in the never
transfused cohort had iron overload, indicating that this complica-

AC K N OW L E D G E M E N T S

tion occurs as a consequence of the disease itself, in addition to its

The Pyruvate Kinase deficiency Natural History Study was sup-

management. Similarly, the occurrence of osteoporosis and pulmo-

ported by research funding from Agios Pharmaceuticals, Inc. We

nary hypertension in patients who had not undergone transfusion or

would like to thank the patients taking part in the Pyruvate Kinase

splenectomy suggests that they may be due to PK deficiency itself.

deficiency Natural History Study. Editorial assistance with manu-

All three of these complications are also reported in patients with

script preparation was provided by Christine Ingleby, PhD, CMPP,

β-thalassemia, where they are considered to be caused, at least in

Excel Scientific Solutions, Horsham, UK, and supported by Agios

part, by ineffective erythropoiesis. 21-23

Pharmaceuticals, Inc.

Osteoporosis rates were significantly higher in the PK deficiency
population than the general population. The lack of osteoporosis in

C O N FL I C T O F I N T E R E S T

the matched healthy population is likely due to the relatively young
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age of the cohorts (mean age, 36 years). A high rate of other bone
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Watson Health. EJvB has received research support from Agios,

fractures,13 is seen in patients with PK deficiency, similar to the bone
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disease encountered in thalassemia. 24
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search. In addition, there may be a risk of a relative underreport-

Genentech; has served as a consultant for Pfizer; has served on

ing of conditions in the general population as the claims database
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